Fortress Biotech Inc (FBIO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.72+0.37%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · FBIO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -88.9% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 46.3% |
Growth built into the price is above our model estimate.
The price assumes 135.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
FBIO — earnings miss
Dated 2026-03-31
Results of Operations and Financial Condition . On March 31, 2026, Fortress Biotech, Inc. issued a press release to provide a corporate update and to announce its financial results for the year ended December 31, 2025. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or other…
Why it matters: Approval in new markets could greatly increase sales. It also supports Fortress's growth plan.
Supportive ifFDA grants approval for ZYCUBO in at least one new international market.
Worry ifFDA delays or denies approval for ZYCUBO in new markets.
Why it matters: Updates on dotinurad trials will show progress in development. Good results could help Fortress.
Watch forCrystalys shares good results from the Phase 3 trials for dotinurad.
Also watch forCrystalys reports bad results or delays in the Phase 3 trials for dotinurad.
Why it matters: Increased royalties from ZYCUBO would confirm management's focus on revenue growth. It shows the product's market acceptance.
Supportive ifZYCUBO's royalty revenue will go above $0.2 million next quarter.
Worry ifZYCUBO royalty revenue remains at or below $0.2 million in the next quarter.
Why it matters: The earnings report shows how the company is doing and what may happen next.
Watch forFortress Biotech announces a date for its next earnings report.
Also watch forNo announcement of an earnings date by the end of the quarter.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$260 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $552 loss on $10,000 · 5.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,003 loss on $10,000 · 30.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: If revenue growth speeds up, it could signal a stronger market for Fortress Biotech.
Supportive ifHealth Care sector revenue growth is speeding up toward 10% or more.
Worry ifRevenue growth stays below 10% or keeps slowing down.
Why it matters: Emrosi sales growth shows good market access and sales growth. It shows effective strategies.
Supportive ifEmrosi net product revenues exceed $17.8 million in the next quarter.
Worry ifEmrosi net product revenues fall below $17.8 million in the next quarter.
Why it matters: A strong cash position helps Fortress fund its pipeline. It also reduces debt and supports growth.
Supportive ifCash and cash equivalents exceed $200 million after Q3 2026.
Worry ifCash and cash equivalents fall below $150 million after Q3 2026.